UK Researchers Adapt COVID‑19 Vaccine Platform to Tackle New Ebola Outbreak

When the first cases of a new Ebola strain surfaced in Uganda earlier this year, the alarm bells rang loud and clear. Health officials scrambled for answers, while virologists in the UK quietly rolled up their sleeves and turned to a familiar piece of biotech – the very platform that helped deliver the AstraZeneca COVID‑19 jab.

At the University of Oxford’s Jenner Institute, Dr. Eleanor Marsh and her team are tinkering with the same chimp‑adenovirus vector that carried the spike protein of SARS‑CoV‑2. Instead of the spike, they’re now inserting a gene that encodes a key Ebola surface protein, the glycoprotein that the virus uses to invade human cells.

“It’s a bit like using a tried‑and‑tested delivery truck to carry a new cargo,” Marsh explained in a recent interview. “We already know the vehicle works, we just need to load it with the right payload and get it out there quickly.”

The advantage of this approach is speed. The AstraZeneca platform has a proven manufacturing pipeline, regulatory track record and, crucially, a safety profile that regulators worldwide already understand. By piggy‑backing on that, the Oxford team hopes to shave months off the usual vaccine development timeline.

Funding for the project has been pieced together from a mix of UK government emergency grants, charitable contributions from the Wellcome Trust, and a modest boost from AstraZeneca itself, which has pledged to share its proprietary vector technology for “humanitarian use.”

Clinical testing is already underway. Phase 1 trials, involving a small cohort of healthy volunteers, are slated to begin at the Royal Free Hospital later this summer. If those go smoothly, a larger Phase 2/3 study across multiple sites in Uganda, Rwanda and the Democratic Republic of Congo could follow by early 2027.

Experts caution that no vaccine is a silver bullet. “We still need robust surveillance, rapid diagnostics and effective treatment centres,” noted Dr. Amara Okello, an epidemiologist with the World Health Organization. “But having a vaccine ready in the near term would be a game‑changer for outbreak control.”

Meanwhile, the British public remains largely unaware of the work happening behind the lab doors. Marsh hopes that by the time the vaccine is ready for rollout, the story of an old COVID‑19 jab reborn as an Ebola shield will inspire confidence in science and demonstrate the value of flexible, platform‑based vaccine design.